Analytical Data
-
Gene name
IL-36 beta
- Application
-
Alternative Names
IL1F8; IL36b; FIL1; FIL1-(ETA); FIL1H; IL-1F8; IL-1H2; IL1-ETA; IL1H2; Interleukin 36, Beta; Interleukin-1 Family Member 8; Interleukin-1 homolog 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
> 90% as determined by SDS-PAGE.
-
Uniprot
Q9NZH7
-
Expression Region
Met1~Ile158
-
Molecular Weight
22kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-36 beta, a member of the interleukin-1 (IL-1) superfamily, has garnered significant attention in immunological research due to its pivotal role in the regulation of inflammatory responses and its association with various autoimmune and inflammatory diseases. Identified as a pro-inflammatory cytokine, IL-36 beta is primarily produced by activated immune cells, including dendritic cells and macrophages. Its expression is notably upregulated in conditions such as psoriasis, where it contributes to the pathogenesis by promoting T-helper 17 (Th17) cell differentiation and enhancing the secretion of other inflammatory mediators. The discovery of its specific receptors, IL-36R, has further elucidated its signaling pathways, making it a potential therapeutic target for inflammatory disorders. Recent studies have focused on characterizing the biological functions and mechanisms of action of recombinant IL-36 beta, exploring its effects on immune cell interactions and cytokine profiles. These investigations aim to develop novel therapeutic strategies that could mitigate excessive inflammation and restore homeostasis in diseases characterized by aberrant IL-36 beta signaling. Understanding the nuances of IL-36 beta's role in immune regulation could pave the way for innovative treatments that harness its pro-inflammatory properties while minimizing detrimental effects, addressing an unmet need in the management of chronic inflammatory conditions.
